ArticleDer Internist2017
[Baroreceptor activation therapy for therapy-resistant hypertension: indications and patient selection : Recommendations of the BAT consensus group 2017].
Article in Der Internist, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Neurocardiology: translational advancements and potential.The Journal of physiology · 2025Review
- Successful baroreflex activation therapy in a case of therapy-resistant renovascular hypertension.Clinical research in cardiology : official journal of the German Cardiac Society · 2023Article
- Effect of baroreflex activation therapy on dipping pattern in patients with resistant hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2023Observational
- Impact of medication adherence on the efficacy of Baroreflex activation therapy.Journal of clinical hypertension (Greenwich, Conn.) · 2022Article
- Eligibility for Baroreflex Activation Therapy and medication adherence in patients with apparently resistant hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2021Article
- Implant-Mediated Therapy of Arterial Hypertension.Current hypertension reports · 2020Review
- Kidney protective effects of baroreflex activation therapy in patients with resistant hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2018Article
- [Baroreflex activation therapy : Indication and evidence in resistant hypertension and heart failure].Der Internist · 2018Review
- [Therapy-resistant and therapy-refractory arterial hypertension].Der Internist · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Baroreceptor activation therapy (BAT) has been available for several years for treatment of therapy-refractory hypertension (trHTN). This procedure is currently being carried out in a limited number of centers in Germany, also with the aim of offering a high level of expertise through sufficient experience; however, a growing number of patients who are treated with BAT experience problems that treating physicians are confronted with in routine medical practice. In order to address these problems, a consensus conference was held with experts in the field of trHTN in November 2016, which summarizes the current evidence and experience as well as the problem areas in handling BAT patients.
Indexed as
Identifiers
28835975What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.